Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus

Zacks11-08

Immunovant, Inc. IMVT reported second-quarter fiscal 2025 net loss of 74 cents per share, wider than the Zacks Consensus Estimate of a loss of 61 cents. The reported figure is also wider than the year...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2482484318?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/H9DYdttPy00EKBHhcxtlCA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9f2a2e04a053cda7a8c096e532e43d28","is_english":true,"pubTime":"2024-11-08 23:38","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2482484318","market":"us","top_or_hot":-1,"title":"Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus","media":"Zacks","content":"<div>\n<p>Immunovant, Inc. IMVT reported second-quarter fiscal 2025 net loss of 74 cents per share, wider than the Zacks Consensus Estimate of a loss of 61 cents. The reported figure is also wider than the year...</p>\n\n<a href=\"https://finance.yahoo.com/news/immunovants-q2-loss-wider-expected-153800243.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmunovant's Q2 Loss Wider Than Expected, Pipeline in Focus\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-08 23:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/immunovants-q2-loss-wider-expected-153800243.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Immunovant, Inc. IMVT reported second-quarter fiscal 2025 net loss of 74 cents per share, wider than the Zacks Consensus Estimate of a loss of 61 cents. The reported figure is also wider than the year...</p>\n\n<a href=\"https://finance.yahoo.com/news/immunovants-q2-loss-wider-expected-153800243.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://finance.yahoo.com/news/immunovants-q2-loss-wider-expected-153800243.html","article_id":"2482484318","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/H9DYdttPy00EKBHhcxtlCA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9f2a2e04a053cda7a8c096e532e43d28"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2482484318","pubTimestamp":1731080280,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Immunovant, Inc. IMVT reported second-quarter fiscal 2025 net loss of 74 cents per share, wider than the Zacks Consensus Estimate of a loss of 61 cents. The reported figure is also wider than the year-ago quarter's loss of 45 cents per share.Currently, Immunovant does not have any approved product in its portfolio. As a result, it has yet to generate revenues.See the ZacksEarnings Calendar to stay ahead of market-making news.Research and development (R&D) expenses totaled $97.3 million, up 103% from the year-ago quarter’s figure. The massive uptick can be attributed to activities in preparation for potential future clinical studies of IMVT-1402, including contract manufacturing costs for drug substance, higher overall clinical study costs related to batoclimab development programs and increased personnel-related expenses.IMVT may also transition its batoclimab CIDP study to a registrational CIDP program with IMVT-1402.The company believes that the data from the ongoing batoclimab CIDP ","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","NVS":"诺华","IMVT":"Immunovant, Inc.","IE00B19Z9P08.USD":"LEGG MASON CLEARBRIDGE US AGGRESSIVE GROWTH \"A\" (USD) INC","BK4007":"制药","BK4566":"资本集团","BK4578":"CAR-T","IE00B19Z9Z06.USD":"Legg Mason ClearBridge - US Aggressive Growth A Acc USD","IE0031619046.USD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY \"A\" (USD) INC","IE00B7SZL793.SGD":"Legg Mason Royce - US Small Cap Opportunity A Acc SGD-H","GD":"通用动力","BK4588":"碎股","BK4550":"红杉资本持仓","BK4123":"调查和咨询服务","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","BK4505":"高瓴资本持仓","IE00B66KJ199.SGD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY  \" A\" (SGD) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","IE00B19Z4B17.USD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY \"A\" (USD) ACC","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BIIB":"渤健公司","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","IE00B894F039.SGD":"Legg Mason ClearBridge - US Aggressive Growth A Acc SGD-H","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU0234570918.USD":"高盛全球核心股票组合Acc Close","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","MG":"Mistras Group","BK4516":"特朗普概念","ALLO":"Allogene Therapeutics Inc.","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","BK4532":"文艺复兴科技持仓","BK4187":"航天航空与国防","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC"},"translate_title":"Immunovant第二季度亏损超出预期，管道成为焦点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BIIB":1,"NVS":1,"MG":1,"GD":1,"ALLO":1,"IMVT":0.9},"content_text":"Immunovant, Inc. IMVT reported second-quarter fiscal 2025 net loss of 74 cents per share, wider than the Zacks Consensus Estimate of a loss of 61 cents. The reported figure is also wider than the year-ago quarter's loss of 45 cents per share.\nCurrently, Immunovant does not have any approved product in its portfolio. As a result, it has yet to generate revenues.\nSee the Zacks Earnings Calendar to stay ahead of market-making news. \nIMVT’s Q3 Results in Detail\nResearch and development (R&D) expenses totaled $97.3 million, up 103% from the year-ago quarter’s figure. The massive uptick can be attributed to activities in preparation for potential future clinical studies of IMVT-1402, including contract manufacturing costs for drug substance, higher overall clinical study costs related to batoclimab development programs and increased personnel-related expenses.\nGeneral and administrative expenses amounted to $18.5 million, up 33% on a year-over-year basis. The rise was primarily due to an increase in personnel-related expenses, legal and other professional fees, along with information technology costs.\nAs of Sept. 30, 2024, Immunovant had a cash balance of $472.9 million compared with $560 million as of June 30, 2023.\nIMVT’s Key Pipeline Updates\nImmunovant has crowned IMVT-1402,a next-generation FcRn inhibitor, as the lead asset going forward given its broad potential across several indications.\nThe company is on track to initiate four to five potentially registrational programs for IMVT-1402 over the next fiscal year (ending March 31, 2025). Over the next two fiscal years, the company plans to initiate studies in a total of 10 indications for IMVT-1402. The company also expects to achieve financial efficiencies in its IMVT-1402 development program by leveraging the data already available from batoclimab studies.\nThe broad set of late-stage studies expected to be initiated for IMVT-1402 will include several indications, including Graves’ disease (GD), Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).\nYear to date, shares of Immunovant have plunged 29% compared with the industry’s 1.4% decline.\nImage Source: Zacks Investment Research\nImmunovant is evaluating its second candidate, batoclimab, in several ongoing mid-late-stage studies across different autoimmune indications, including GD, MG, CIDP and thyroid eye disease (TED).\nIn September, the company announced positive data from the mid-stage study on, batoclimab, which is being developed for GD. Leveraging the encouraging results from the phase IIa GD study ofbatoclimab, Immunovant is currently gearing up to initiate a pivotal study of IMVT-1402 for the same indication by the end of 2024.\nTop-line results from the MG study of batoclimab are expected by the end of this fiscal year (March 31, 2025).\nIMVT may also transition its batoclimab CIDP study to a registrational CIDP program with IMVT-1402. The company believes that the data from the ongoing batoclimab CIDP study will substantially benefit the design of a potentially registrational study with IMVT-1402 for the same indication. Top-line data from the phase IIb study of batoclimab for CIDP is expected by March 31, 2025.\nFurthermore, the company is also scheduled to share top-line data from the late-stage TED study of batoclimab in the second half of 2025.\n\nImmunovant, Inc. Price and Consensus\n\nImmunovant, Inc. price-consensus-chart | Immunovant, Inc. Quote\n\nIMVT’s Zacks Rank and Stocks to Consider\nImmunovant currently carries a Zacks Rank #3 (Hold).\nSome better-ranked pharma stocks are Allogene Therapeutics ALLO, Biogen BIIB and Novartis NVS, each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.\nAllogene Therapeutics’ loss estimates have remained constant at $1.41 per share for 2024 over the past 60 days, while that for 2025 has narrowed from $1.46 to $1.45 per share. ALLO’s shares have lost 0.6% year to date.\nAllogene Therapeutics’ earnings beat estimates in three of the trailing four quarters and matched once, delivering an average surprise of 9.42%.\nBiogen’s earnings estimates have risen from $16.12 to $16.37 per share for 2024 over the past 60 days, while that for 2025 has increased from $17.09 to $17.15. BIIB’s shares have lost 32.8% year to date.\nBiogen’s earnings beat estimates in three of the trailing four quarters and missed the same in one, delivering an average surprise of 9.99%.\nNovartis’ earnings estimates have risen from $7.50 to $7.56 per share for 2024 over the past 60 days, while that for 2025 has increased from $8.30 to $8.33. NVS’ shares have risen 6.1% year to date.\nNovartis’ earnings beat estimates in three of the trailing four quarters and missed the same in one, delivering an average surprise of 2.22%.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nNovartis AG (NVS) : Free Stock Analysis Report\nBiogen Inc. (BIIB) : Free Stock Analysis Report\nAllogene Therapeutics, Inc. (ALLO) : Free Stock Analysis Report\nImmunovant, Inc. (IMVT) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2482484318"}